Health-related quality of life after renal denervation in patients with treatment-resistant hypertension

Hypertension

Volumn 60, Issue 6, 2012, Pages 1479-1484

  Lambert, Gavin W ^a,c   Hering, Dagmara ^a,f   Esler, Murray D ^a,c   Marusic, Petra ^a   Lambert, Elisabeth A ^a,c,d   Tanamas, Stephanie K ^b   Shaw, Jonathan ^b,c   Krum, Henry ^c   Dixon, John B ^a,c   Barton, David A ^d,e   Schlaich, Markus P ^a,c  

^a Baker IDI Heart   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Southern Health   (Australia)

^f MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

ablation; depression; high blood pressure; sympathetic nervous system

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; BLOOD PRESSURE REGULATION; CATHETER ABLATION; CONTROLLED STUDY; DATA BASE; DIASTOLIC BLOOD PRESSURE; FATIGUE; FEMALE; HUMAN; KIDNEY DENERVATION; LIBIDO; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RESISTANT HYPERTENSION; SELF REPORT; SHORT FORM 36; STATE TRAIT ANXIETY INVENTORY; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT;

AGED; BLOOD PRESSURE; DEPRESSION; EMOTIONS; FEMALE; HEALTH SURVEYS; HUMANS; HYPERTENSION; KIDNEY; MALE; MENTAL HEALTH; MIDDLE AGED; QUALITY OF LIFE; SOCIAL BEHAVIOR; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84870255223     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.200865     Document Type: Article

References (40)

1. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M; Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-1909.
2. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-917.
3. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-1281.
4. Freyberg RH, Peet MM. The effect on the kidney of bilateral splanchnicectomy in patients with hypertension. J Clin Invest. 1937;16:49-65.
5. Hoobler SW, Manning JT, Paine WG, McClellan SG, Helcher PO, Renfert H Jr, Peet MM, Kahn EA. The effects of splanchnicectomy on the blood pressure in hypertension; a controlled study. Circulation. 1951;4:173-183.
6. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. JAMA. 1953;152:1501-1504.
7. Page IH, Heuer GJ. The effect of renal denervation on the level of arterial blood pressure and renal function in essential hypertension. J Clin Invest. 1935;14:27-30.
8. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, Hoppe UC. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59:901-909.
9. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Böhm M, Cremers B, Esler MD, Schlaich MP. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:1250-1257.
10. Schlaich MP, Hering D, Sobotka PA, Krum H, Esler MD. Renal denervation in human hypertension: mechanisms, current findings, and future prospects. Curr Hypertens Rep. 2012;14:247-253.
11. Crile G. The clinical results of celiac ganglionectomy in the treatment of essential hypertension. Ann Surg. 1938;107:909-916.
12. Mancia G, De Backer G, Dominiczak A et al; ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25:1751-1762.
13. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and-a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-1419.
14. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932-934.
15. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, Dwyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002;25:829-834.
16. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
17. Statistics ABo. National Health Survey SF-36 Population Norms Australia. Canberra, Australia: Australian Bureau of Statistics; 1997.
18. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories-IA and-II in psychiatric outpatients. J Pers Assess. 1996;67:588-597.
19. Spielberger CD. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press; 1983.
20. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940-1946.
21. Bardage C, Isacson DG. Hypertension and health-related quality of life. an epidemiological study in Sweden. J Clin Epidemiol. 2001;54:172-181.
22. Lawrence WF, Fryback DG, Martin PA, Klein R, Klein BE. Health status and hypertension: a population-based study. J Clin Epidemiol. 1996;49:1239-1245.
23. Trevisol DJ, Moreira LB, Kerkhoff A, Fuchs SC, Fuchs FD. Health-related quality of life and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2011;29:179-188.
24. Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, Klerman GL, Williams GH. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986;314:1657-1664.
25. Testa MA, Anderson RB, Nackley JF, Hollenberg NK. Quality of life and antihypertensive therapy in men: a comparison of captopril with enalapril-the Quality-of-Life Hypertension Study Group. N Engl J Med. 1993;328:907-913.
26. Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, Carretero-Ares JL, Arzua-Mouronte D, Herreros-Fernandez V. Health-related quality of life of subjects with known and unknown hypertension: results from the population-based Hortega study. J Hypertens. 2003;21:1283-1289.
27. Hayes DK, Denny CH, Keenan NL, Croft JB, Greenlund KJ. Health-related quality of life and hypertension status, awareness, treatment, and control: National Health and Nutrition Examination Survey, 2001-2004. J Hypertens. 2008;26:641-647.
28. Korhonen PE, Kivelä SL, Kautiainen H, Järvenpää S, Kantola I. Health-related quality of life and awareness of hypertension. J Hypertens. 2011;29:2070-2074.
29. Poljicanin T, Ajdukovi D, Sekerija M, Pibernik-Okanovi M, Metelko Z, Vuleti Mavrinac G. Diabetes mellitus and hypertension have comparable adverse effects on health-related quality of life. BMC Public Health. 2010;10:12.
30. Jacobson AM, de Groot M, Samson JA. The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care. 1994;17:267-274.
31. Chow FY, Briganti EM, Kerr PG, Chadban SJ, Zimmet PZ, Atkins RC. Health-related quality of life in Australian adults with renal insufficiency: a population-based study. Am J Kidney Dis. 2003;41:596-604.
32. Jenkinson C, Jenkinson D, Shepperd S, Layte R, Petersen S. Evaluation of treatment for congestive heart failure in patients aged 60 years and older using generic measures of health status (SF-36 and COOP charts). Age Ageing. 1997;26:7-13.
33. Dixon JB, Dixon ME, O'Brien PE. Quality of life after lap-band placement: influence of time, weight loss, and comorbidities. Obes Res. 2001;9:713-721.
34. Grimm RH Jr, Grandits GA, Cutler JA, Stewart AL, McDonald RH, Svendsen K, Prineas RJ, Liebson PR. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med. 1997;157:638-648.
35. Wiklund I, Halling K, Rydén-Bergsten T, Fletcher A. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Blood Press. 1997;6:357-364.
36. Ciriello J, Calaresu FR. Hypothalamic projections of renal afferent nerves in the cat. Can J Physiol Pharmacol. 1980;58:574-576.
37. Calaresu FR, Ciriello J. Renal afferent nerves affect discharge rate of medullary and hypothalamic single units in the cat. J Auton Nerv Syst. 1981;3:311-320.
38. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension. 1995;25(4 pt 2):878-882.
39. Foote SL, Bloom FE, Aston-Jones G. Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol Rev. 1983;63:844-914.
40. Svensson TH. Peripheral, autonomic regulation of locus coeruleus noradrenergic neurons in brain: putative implications for psychiatry and psychopharmacology. Psychopharmacology (Berl). 1987;92:1-7.